{
    "info": {
        "nct_id": "NCT03672695",
        "official_title": "An International Phase Ib Multicentre Study to Characterize the Safety and Tolerability of Intravenously Administered S64315, a Selective Mcl-1 Inhibitor, in Combination With Orally Administered Venetoclax, a Selective Bcl-2 Inhibitor in Patients With Acute Myeloid Leukaemia (AML).",
        "inclusion_criteria": "1. Male or female aged ≥ 18 years;\n2. Patients with cytologically confirmed and documented de novo, secondary or therapy-related AML as defined by World Health Organization (WHO) 2016 classification (Arber, 2016), excluding acute promyelocytic leukaemia (APL, French-American British M3 classification):\n\n   * With relapsed or refractory disease without established alternative therapy or\n   * Secondary to MDS treated at least by hypomethylating agent and without established alternative therapy or\n   * ≥ 65 years not previously treated for AML and who are not candidates for intensive chemotherapy nor candidates for established alternative therapy\n3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n4. Able to comply with study procedures\n5. Adequate renal function within 7 days before the inclusion of the patient defined as:\n\n   • Serum creatinine ≤ 1.5 x ULN (upper normal limit) or calculated creatinine clearance (determined by MDRD) > 50 mL/min/1.73m2\n6. Adequate hepatic function within 7 days before the inclusion of the patient defined as:\n\n   * AST and ALT ≤ 1.5 x ULN\n   * Total serum bilirubin level ≤ 1.5 x ULN, except for patients with known Gilbert's syndrome, who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Participant already enrolled and treated in the study\n2. Pregnancy, breastfeeding or possibility of becoming pregnant during the study\n3. Participation in another interventional study requiring investigational treatment intake at the same time or within 2 weeks or at least 5 halflives (whichever is longer) prior to first dose of IMP (participation in non-interventional registries or epidemiological studies is allowed). In case of biologic agents with a long half life such as CART cells, immune checkpoint antibodies, bispecific antibodies a flat wash-out of 28 days will be acceptable\n4. Presence of ≥ CTCAE Grade 2 toxicity (except alopecia of any grade) due to prior cancer therapy, according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE, version 4.03).\n5. Known carriers of HIV antibodies\n6. Known history of significant liver disease\n7. Uncontrolled hepatitis B or C infection\n8. Known active acute or chronic pancreatitis\n9. History of myocardial infarction (MI), unstable angina pectoris, coronary artery bypass graft (CABG) within 6 months prior to starting study treatment\n10. Any factors that could increase the risk of QTc prolongation or risk of arrhythmic events.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "• Serum creatinine ≤ 1.5 x ULN (upper normal limit) or calculated creatinine clearance (determined by MDRD) > 50 mL/min/1.73m2",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ≤ 1.5 x ULN (upper normal limit)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated creatinine clearance (determined by MDRD) > 50 mL/min/1.73m2",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "mL/min/1.73m2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* With relapsed or refractory disease without established alternative therapy or",
            "criterions": [
                {
                    "exact_snippets": "With relapsed or refractory disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "without established alternative therapy",
                    "criterion": "established alternative therapy",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥ 65 years not previously treated for AML and who are not candidates for intensive chemotherapy nor candidates for established alternative therapy",
            "criterions": [
                {
                    "exact_snippets": "≥ 65 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 65,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not previously treated for AML",
                    "criterion": "prior AML treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not candidates for intensive chemotherapy",
                    "criterion": "intensive chemotherapy candidacy",
                    "requirements": [
                        {
                            "requirement_type": "candidacy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "nor candidates for established alternative therapy",
                    "criterion": "established alternative therapy candidacy",
                    "requirements": [
                        {
                            "requirement_type": "candidacy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST and ALT ≤ 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "AST ... ≤ 1.5 x ULN",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT ≤ 1.5 x ULN",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total serum bilirubin level ≤ 1.5 x ULN, except for patients with known Gilbert's syndrome, who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Total serum bilirubin level ≤ 1.5 x ULN",
                    "criterion": "total serum bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with known Gilbert's syndrome, who are excluded if total bilirubin > 3.0 x ULN",
                    "criterion": "total bilirubin level in patients with known Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with known Gilbert's syndrome, who are excluded if ... direct bilirubin > 1.5 x ULN",
                    "criterion": "direct bilirubin level in patients with known Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Male or female aged ≥ 18 years;",
            "criterions": [
                {
                    "exact_snippets": "Male or female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "aged ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Able to comply with study procedures",
            "criterions": [
                {
                    "exact_snippets": "Able to comply with study procedures",
                    "criterion": "ability to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Secondary to MDS treated at least by hypomethylating agent and without established alternative therapy or",
            "criterions": [
                {
                    "exact_snippets": "Secondary to MDS",
                    "criterion": "myelodysplastic syndrome (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "cause of condition",
                            "expected_value": "secondary to MDS"
                        }
                    ]
                },
                {
                    "exact_snippets": "treated at least by hypomethylating agent",
                    "criterion": "prior treatment with hypomethylating agent",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without established alternative therapy",
                    "criterion": "established alternative therapy",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Adequate hepatic function within 7 days before the inclusion of the patient defined as:",
            "criterions": [
                {
                    "exact_snippets": "Adequate hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Adequate renal function within 7 days before the inclusion of the patient defined as:",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 7 days before the inclusion of the patient",
                    "criterion": "timing of renal function assessment",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before inclusion"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients with cytologically confirmed and documented de novo, secondary or therapy-related AML as defined by World Health Organization (WHO) 2016 classification (Arber, 2016), excluding acute promyelocytic leukaemia (APL, French-American British M3 classification):",
            "criterions": [
                {
                    "exact_snippets": "cytologically confirmed and documented de novo, secondary or therapy-related AML as defined by World Health Organization (WHO) 2016 classification (Arber, 2016)",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "cytologically confirmed and documented"
                        },
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "de novo",
                                "secondary",
                                "therapy-related"
                            ]
                        },
                        {
                            "requirement_type": "classification system",
                            "expected_value": "World Health Organization (WHO) 2016 classification"
                        }
                    ]
                },
                {
                    "exact_snippets": "excluding acute promyelocytic leukaemia (APL, French-American British M3 classification)",
                    "criterion": "acute promyelocytic leukaemia (APL)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "9. History of myocardial infarction (MI), unstable angina pectoris, coronary artery bypass graft (CABG) within 6 months prior to starting study treatment",
            "criterions": [
                {
                    "exact_snippets": "History of myocardial infarction (MI) ... within 6 months prior to starting study treatment",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to starting study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris ... within 6 months prior to starting study treatment",
                    "criterion": "unstable angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to starting study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "coronary artery bypass graft (CABG) within 6 months prior to starting study treatment",
                    "criterion": "coronary artery bypass graft (CABG)",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to starting study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Presence of ≥ CTCAE Grade 2 toxicity (except alopecia of any grade) due to prior cancer therapy, according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE, version 4.03).",
            "criterions": [
                {
                    "exact_snippets": "Presence of ≥ CTCAE Grade 2 toxicity ... due to prior cancer therapy",
                    "criterion": "toxicity due to prior cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE Grade"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except alopecia of any grade",
                    "criterion": "alopecia due to prior cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "any grade"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Known history of significant liver disease",
            "criterions": [
                {
                    "exact_snippets": "Known history of significant liver disease",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participant already enrolled and treated in the study",
            "criterions": [
                {
                    "exact_snippets": "Participant already enrolled ... in the study",
                    "criterion": "study enrollment",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participant already ... treated in the study",
                    "criterion": "study treatment",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Known carriers of HIV antibodies",
            "criterions": [
                {
                    "exact_snippets": "Known carriers of HIV antibodies",
                    "criterion": "HIV antibody carrier status",
                    "requirements": [
                        {
                            "requirement_type": "carrier status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Participation in another interventional study requiring investigational treatment intake at the same time or within 2 weeks or at least 5 halflives (whichever is longer) prior to first dose of IMP (participation in non-interventional registries or epidemiological studies is allowed). In case of biologic agents with a long half life such as CART cells, immune checkpoint antibodies, bispecific antibodies a flat wash-out of 28 days will be acceptable",
            "criterions": [
                {
                    "exact_snippets": "Participation in another interventional study requiring investigational treatment intake at the same time or within 2 weeks or at least 5 halflives (whichever is longer) prior to first dose of IMP",
                    "criterion": "participation in another interventional study requiring investigational treatment intake",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to first dose of IMP",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "halflives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participation in non-interventional registries or epidemiological studies is allowed",
                    "criterion": "participation in non-interventional registries or epidemiological studies",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "In case of biologic agents with a long half life such as CART cells, immune checkpoint antibodies, bispecific antibodies a flat wash-out of 28 days will be acceptable",
                    "criterion": "prior exposure to biologic agents with a long half life (CART cells, immune checkpoint antibodies, bispecific antibodies)",
                    "requirements": [
                        {
                            "requirement_type": "wash-out period before first dose of IMP",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Uncontrolled hepatitis B or C infection",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hepatitis B or C infection",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled hepatitis B or C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Known active acute or chronic pancreatitis",
            "criterions": [
                {
                    "exact_snippets": "Known active acute or chronic pancreatitis",
                    "criterion": "pancreatitis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Any factors that could increase the risk of QTc prolongation or risk of arrhythmic events.",
            "criterions": [
                {
                    "exact_snippets": "factors that could increase the risk of QTc prolongation",
                    "criterion": "risk factors for QTc prolongation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "factors that could increase the ... risk of arrhythmic events",
                    "criterion": "risk factors for arrhythmic events",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Pregnancy, breastfeeding or possibility of becoming pregnant during the study",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "possibility of becoming pregnant during the study",
                    "criterion": "possibility of becoming pregnant during the study",
                    "requirements": [
                        {
                            "requirement_type": "possibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}